Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Shoreline Biosciences is developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage cellular immunotherapies that are intelligently designed for greater potency and persistence, to create safe, effective, and affordable immunotherapies for the treatment of seriously ill patients. Shoreline’s proprietary cell therapy platform is based on deep expertise in iPSC differentiation […]
Exo Therapeutics leverages its ExoSite™ platform to develop a deep pipeline of potent drug candidates that bind exosites – distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Enzymes play key roles in all metabolic processes, such as destroying toxins and aiding digestion. This critical […]
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases. Garuda’s platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched, transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant, […]